Methotrexate and oral ulceration

British Dental Journal

Volumn 198, Issue 2, 2005, Pages 83-85

  Deeming, G M J ^a   Collingwood, J ^a   Pemberton, M N ^a  

^a UNIVERSITY DENTAL HOSPITAL OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; MOUTH ULCER; RHEUMATOID ARTHRITIS; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; ORAL ULCER;

EID: 13244291433     PISSN: 00070610     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bdj.4811972     Document Type: Article

References (18)

1. Olsen E A. The pharmacology of methotrextate. J Am Acad Dermatol 1991; 25: 306-318.
2. British National Formulary. 45. London: BMA, RPS, 2003.
3. Schroder O, Stein J. Low dose methotrexate in inflammatory bowel disease: current status and future directions. Am J Gastroenterol 2003; 98: 530-537.
4. Smith J R, Rosembaum J T. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001; 85: 1220-1224.
5. Choi H K, Hernan M A, Seeger J D, Robins J M, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-1177.
6. Knox J J, Puodziunas A L V, Feld R. Chemotherapy-induced oral mucositis: prevention and management. Drugs Aging 2000; 17: 257-267.
7. West S G. Methotrexate toxicity. Rheum Dis Clin North Am 1997; 23: 883-915.
8. Major S. UK introduces measures to reduce errors with methotrexate. Br Med J 2003; 327: 70.
9. Singh G, Fries J F, Williams C A, Zatarain E, Spitz P, Bloch A. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 188-194.
10. Sosin M, Handa S. Low dose methotrexate and bone marrow suppression. Br Med J 2003; 326: 266-267.
11. Kremer J M, Phelps C T. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138-145.
12. Ince A, Yazici Y, Hamuryudan V, Yazici H. The frequency and clinical characteristics of methotrexate (MTX) oral toxicity in rheumatoid arthritis (RA): A masked and controlled study. Clin Rheumatol 1996; 15: 491-494.
13. Jackson R. Biological effects of folic acid antagonists with antineoplastic activity. Pharmacol Ther 1984; 25: 61-82.
14. Shirozky J B, Neville C, Esdaile J M et al. Low-dose methotrexate with leucovirin (folinic acid) in the management of rheumatoid arthritis: results of a muticenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795-803.
15. Stewart K A, Mackenzie A H, Clough J D, Wilke W S. Folate supplementation in methotrexate-treated rheumatoid arthritis patients. Semin Arthritis Rheum 1991; 20: 332-338.
16. Ortiz Z, Shea B, Suarez-Almazor M, Moher D, Wells G A, Tugwell P. The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis. A metaanalysis of randomized controlled trials. J Rheumatol 1998; 25: 36-43.
17. Endresen G K M, Husby G. Folate supplementation during methotrexate treatment of patients with rheumatoid arthritis. Scand J Rheumatol 2001; 30: 129-134.
18. Morgan S L, Baggott J E, Vaughan W H et al. Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 1994; 121: 833-841.